Gapping up
In reaction to earnings/guidance:
- SUPN +16%, SMCI +13.1%, HBM +6.4%, NP +5.6%, VRT +4.3%, CLH +3.4%, VST +2.9%, BTG +2.7%, NEX +2.5%, JBGS +2%, HLT +2%, CC +1.7%, HTA +1.7%, TX +1.5%, DS +1.2%, SGRY +0.9%
Other news:
- LOGC +9.8% (receives FDA Fast Track designation for LB-001 as treatment for methylmalonic acidemia)
- BMY +3.8% (Bristol-Myers and MyoKardia (MYOK) announce expiration of HSR Act Waiting Period)
- DVA +2.4% (issues statement regarding Proposition 23 being voted down in California)
- LLY +2.1% (provides update on FDA general surveillance inspections)
- FAF +2% (increases dividend)
- SLNO +1.7% (presents body composition data from Phase III trial)
- NDAQ +1.3% (reports October 2020 metrics)
- LX +1% (provides update on regulatory development; Online microcredit accounts for less than 1% of loan financing)
Analyst comments:
- XPEV +5.1% (initiated with a Buy at Citigroup)
- ADTN +3.6% (upgraded to Buy from Hold at Jefferies)
- TER +3.5% (upgraded to Buy from Neutral at Goldman)
- AMD +3.4% (upgraded to Conviction Buy from Neutral at Goldman)
- BIDU +3.2% (upgraded to Overweight from Equal Weight at Barclays)
- AMZN +2.8% (upgraded to Buy from Hold at China Renaissance)